

# Eduardo Vilar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/671847/publications.pdf>

Version: 2024-02-01

90  
papers

4,973  
citations

126907

33  
h-index

95266

68  
g-index

94  
all docs

94  
docs citations

94  
times ranked

8457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. <i>Gut</i> , 2022, 71, 938-949.	12.1	25
2	Sensei: how many samples to tell a change in cell type abundance?. <i>BMC Bioinformatics</i> , 2022, 23, 2.	2.6	2
3	Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy. <i>Methods in Molecular Biology</i> , 2022, 2435, 95-105.	0.9	1
4	Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. <i>Journal of Genetic Counseling</i> , 2022, 31, 949-955.	1.6	4
5	Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. <i>Nature Communications</i> , 2022, 13, 1199.	12.8	66
6	Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer. <i>PLoS Genetics</i> , 2022, 18, e1010163.	3.5	8
7	Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs. <i>Cancer Prevention Research</i> , 2022, 15, 279-284.	1.5	4
8	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	52
9	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	2.3	17
10	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. <i>Gut</i> , 2021, 70, 555-566.	12.1	37
11	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , 2021, 124, 797-804.	6.4	16
12	Duodenal Adenomas and Cancer in MUTYH-associated Polyposis: An International Cohort Study. <i>Gastroenterology</i> , 2021, 160, 952-954.e4.	1.3	20
13	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021, 26, 71-82.	2.0	4
14	The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells. <i>Cancer Research</i> , 2021, 81, 2760-2773.	0.9	7
15	Telomere dysfunction instigates inflammation in inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28
16	Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. <i>Cancer Prevention Research</i> , 2021, 14, 851-862.	1.5	8
17	Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. <i>Gastroenterology</i> , 2021, 161, 1288-1302.e13.	1.3	56
18	Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). <i>Cancer Prevention Research</i> , 2021, 14, 325-336.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Immune Activation in Mismatch Repairâ€“Deficient Carcinogenesis: More Than Just Mutational Rate. <i>Clinical Cancer Research</i> , 2020, 26, 11-17.	7.0	61
20	Patients with unexplained mismatch repair deficiency are interested in updated genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 19.	1.5	5
21	Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. <i>Cancer Discovery</i> , 2020, 10, 1635-1644.	9.4	52
22	Telomere dysfunction activates YAP1 to drive tissue inflammation. <i>Nature Communications</i> , 2020, 11, 4766.	12.8	42
23	Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. <i>Genes</i> , 2020, 11, 645.	2.4	57
24	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
25	AGA Clinical Practice Update on Young Adultâ€“Onset Colorectal Cancer Diagnosis and Management: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2415-2424.	4.4	24
26	Comment on â€œA National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancerâ€œ. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, e197-e198.	4.2	1
27	Mismatch Repairâ€“Proficient Colorectal Cancer: Finding the Right TIME to Respond. <i>Clinical Cancer Research</i> , 2019, 25, 5185-5187.	7.0	10
28	Realâ€“Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie</i> , 2019, 131, 4223-4227.	2.0	0
29	Realâ€“Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4179-4183.	13.8	8
30	Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer. <i>Cancer Genetics</i> , 2019, 235-236, 77-83.	0.4	3
31	Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 429-437.	1.3	21
32	Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. <i>Journal of Pathology</i> , 2019, 247, 574-588.	4.5	131
33	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	1.2	170
34	Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition. <i>Cancer Research</i> , 2019, 79, 918-927.	0.9	28
35	Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. <i>Oncotarget</i> , 2019, 10, 3939-3951.	1.8	5
36	Hereditary Gastrointestinal Cancers. , 2019, , 595-611.		0

#	ARTICLE	IF	CITATIONS
37	Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. <i>JAMA Oncology</i> , 2018, 4, 1085.	7.1	62
38	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	1.5	36
39	High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 679-686.	1.5	25
40	Medical Oncology Management of Hereditary Colorectal Cancer. , 2018, , 401-413.		0
41	Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair deficiency and Lynch syndrome. <i>Molecular Carcinogenesis</i> , 2017, 56, 1753-1764.	2.7	13
42	SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of $\beta$ -catenin. <i>Gastroenterology</i> , 2017, 153, 205-218.e8.	1.3	34
43	Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. <i>Nature Medicine</i> , 2017, 23, 878-884.	30.7	285
44	Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. <i>Clinical Cancer Research</i> , 2017, 23, 5246-5254.	7.0	34
45	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.9	116
46	Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome. <i>Familial Cancer</i> , 2017, 16, 357-361.	1.9	14
47	Universal Genetic Testing for Younger Patients With Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 448.	7.1	4
48	<i>In Silico</i> Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation. <i>Cancer Prevention Research</i> , 2017, 10, 580-587.	1.5	9
49	Oncogenic targets <i>Mmp7</i> , <i>S100a9</i> , <i>Nppb</i> and <i>Aldh1a3</i> from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. <i>International Journal of Cancer</i> , 2017, 140, 460-468.	5.1	18
50	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	2.5	65
51	Reply to L.B. Saltz. <i>Journal of Clinical Oncology</i> , 2016, 34, 1560-1561.	1.6	0
52	Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency. <i>Familial Cancer</i> , 2016, 15, 587-591.	1.9	6
53	Genomic Landscape of Colorectal Mucosa and Adenomas. <i>Cancer Prevention Research</i> , 2016, 9, 417-427.	1.5	65
54	Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. <i>Annals of Oncology</i> , 2016, 27, 1068-1074.	1.2	26

#	ARTICLE	IF	CITATIONS
55	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	7.1	57
56	DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. Journal of Clinical Oncology, 2016, 34, 3039-3046.	1.6	86
57	MUTYH-Associated Polyposis. , 2016, , 25-32.		0
58	Overtreatment of Young Adults With Colon Cancer. JAMA Surgery, 2015, 150, 402.	4.3	180
59	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology, 2015, 26, 731-736.	1.2	223
60	Association between KRAS mutation and lung metastasis in advanced colorectal cancer. British Journal of Cancer, 2015, 112, 424-428.	6.4	80
61	High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3544-3549.	1.6	179
62	Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. Colloids and Surfaces B: Biointerfaces, 2015, 136, 694-703.	5.0	39
63	Cancer <i>In Silico</i> Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. Molecular Cancer Therapeutics, 2014, 13, 3230-3240.	4.1	21
64	Establishing a Diagnostic Road Map for <i>MUTYH</i> -Associated Polyposis. Clinical Cancer Research, 2014, 20, 1061-1063.	7.0	10
65	Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genetics, 2014, 207, 495-502.	0.4	19
66	Urinary PGE-M in Colorectal Cancer: Predicting More than Risk?. Cancer Prevention Research, 2014, 7, 969-972.	1.5	11
67	Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. Hereditary Cancer in Clinical Practice, 2014, 12, 1.	1.5	20
68	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Annals of Oncology, 2014, 25, 1032-1038.	1.2	226
69	Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Annals of Oncology, 2014, 25, 2008-2014.	1.2	47
70	Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 154-167.	4.4	113
71	Molecular Dissection of Microsatellite Instable Colorectal Cancer. Cancer Discovery, 2013, 3, 502-511.	9.4	91
72	Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer. Colorectal Cancer, 2013, 2, 243-263.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome. <i>Clinical Cancer Research</i> , 2013, 19, 2280-2282.	7.0	9
74	Pinprick diagnostics. <i>Nature</i> , 2012, 486, 482-483.	27.8	19
75	A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 299-305.	2.6	19
76	Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 395-403.	4.1	127
77	Molecular Predictors of Response to Chemotherapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT/Overlo</i>	2.0	40
78	Micromanaging the Classification of Colon Cancer: The Role of the microRNAome. <i>Clinical Cancer Research</i> , 2011, 17, 7207-7209.	7.0	12
79	MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers. <i>Cancer Research</i> , 2011, 71, 2632-2642.	0.9	140
80	Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). <i>Annals of Oncology</i> , 2010, 21, 1794-1803.	1.2	338
81	Microsatellite instability in colorectal cancer—the stable evidence. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 153-162.	27.6	736
82	Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. <i>Clinical Cancer Research</i> , 2009, 15, 2829-2839.	7.0	57
83	Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. <i>British Journal of Cancer</i> , 2008, 99, 1607-1612.	6.4	79
84	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 221-232.	3.1	142
85	New drug development in digestive neuroendocrine tumors. <i>Annals of Oncology</i> , 2007, 18, 1307-1313.	1.2	27
86	Nuevos retos de la oncología molecular en el cáncer de ovario. <i>Medicina Clínica</i> , 2007, 128, 15-17.	0.6	0
87	Molecular biology of testicular germ cell tumors. <i>Clinical and Translational Oncology</i> , 2006, 8, 846-850.	2.4	6
88	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. <i>Cancer</i> , 2006, 106, 2528-2529.	4.1	0
89	The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. <i>Annals of Oncology</i> , 2006, 17, x108-x112.	1.2	2
90	Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 424.	1.3	2